Blue Jet Healthcare (NSE:BLUEJET) disclosed the outcome of its board meeting held on 3 August 2026, approving unaudited standalone financial results for Q1 FY27, setting a dividend record date of 14 September 2026, and reappointing two key management directors for five-year terms each.
Key Highlights
- Revenue from operations for Q1 FY27 stood at Rs 2,931.13 million, compared to Rs 3,547.58 million in Q1 FY26, reflecting a year-on-year decline in standalone revenue.
- Profit for Q1 FY27 was Rs 782.64 million, against Rs 911.70 million in Q1 FY26, with basic and diluted EPS at Rs 4.51 per share (not annualised).
- The board set 14 September 2026 as the record date for the previously recommended dividend of Rs 1.2 per equity share of face value Rs 2 each for FY2025-26.
- Mr. Akshay B Arora (Whole Time Director and Executive Chairman) and Mr. Shiven Akshay Arora (Managing Director) are each proposed for reappointment for five years from 13 April 2027 to 12 April 2032, subject to shareholder approval at the AGM.
About the Company
Blue Jet Healthcare Limited, listed on NSE under the ticker BLUEJET and headquartered in Navi Mumbai, Maharashtra, manufactures artificial sweeteners, contrast media intermediates, pharmaceutical intermediates, and active pharmaceutical ingredients (APIs). The company operates manufacturing facilities at Shahad, Ambernath (West), and Mahad in Maharashtra, serving the pharmaceutical and healthcare industries.
Announcement in Detail
The board meeting, held on 3 August 2026 between 12:10 PM and 12:27 PM, approved the unaudited standalone financial results for the three months ended 30 June 2026. Total income for the quarter was Rs 3,083.50 million, down from Rs 3,630.12 million in Q1 FY26. Profit before tax came in at Rs 1,059.46 million versus Rs 1,228.60 million a year earlier. KKC and Associates LLP completed a limited review and issued an unmodified conclusion on the statement.
The board also approved the 58th Annual General Meeting, scheduled for 21 September 2026 at 11:00 AM IST via video conferencing. Additionally, M/s KKC and Associates LLP were proposed for reappointment as statutory auditors for a second term of five consecutive years, until the conclusion of the 63rd AGM, subject to shareholder approval. Post the quarter end, the company allotted 1,58,10,276 equity shares at Rs 506 per share via a Qualified Institutional Placement (QIP), aggregating to Rs 8,000 million, as disclosed in the notes to the financial results.
Impact on Investors
Investors will note that the dividend of Rs 1.2 per equity share for FY2025-26 carries a record date of 14 September 2026; shareholders holding shares as of that date will be eligible to receive the payout. The filing shows a year-on-year decline in both revenue from operations and profit after tax for Q1 FY27, which shareholders will observe when assessing the company's near-term financial trajectory.
The disclosed QIP, completed subsequent to the quarter end, involved the allotment of 1,58,10,276 new equity shares, increasing the total paid-up equity share capital beyond its Q1 FY27 level of Rs 346.93 million. The disclosed terms indicate this represents dilution for pre-QIP shareholders, a factor investors will note when reviewing per-share metrics going forward. The reappointment proposals for both senior directors are subject to shareholder approval at the upcoming AGM and have not yet been formally sanctioned.
Sector / Market Context
India's pharmaceutical intermediates and API sector has been a focus of domestic policy support, with the government's Production-Linked Incentive (PLI) scheme for pharmaceuticals targeting increased domestic manufacturing of key starting materials and APIs. According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India remains one of the largest global exporters of generic medicines and intermediates. The contrast media intermediate segment, in which Blue Jet Healthcare operates, serves global imaging and diagnostics supply chains, and demand for such specialised intermediates has been supported by growth in diagnostic imaging procedures across regulated markets.